Research programme: ocular disease therapeutics - Allergan/Voyant Biotherapeutics/University of Utah
Latest Information Update: 05 Aug 2015
At a glance
- Originator Allergan; University of Utah; Voyant Biotherapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Age-related macular degeneration; Eye disorders
Most Recent Events
- 20 Feb 2014 Early research in Eye disorders in USA (unspecified route)
- 20 Feb 2014 Early research in Age-related macular degeneration in USA (unspecified route)